Meningococcal vaccine group B OMV - NIPH

Drug Profile

Meningococcal vaccine group B OMV - NIPH

Alternative Names: Meningococcal vaccine group B outer membrane vesicle vaccine - NIPH

Latest Information Update: 15 Aug 2007

Price : $50

At a glance

  • Originator Norwegian Institute of Public Health
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Meningococcal group B infections

Most Recent Events

  • 09 Jul 2004 No development reported - Phase-III for Meningococcal group B infections in Norway (IM)
  • 09 Jul 2004 No development reported - Clinical-Phase-Unknown for Meningococcal group B infections in Iceland (IM)
  • 09 Jul 2004 No development reported - Clinical-Phase-Unknown for Meningococcal group B infections in Chile (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top